Study design (if review, criteria of inclusion for studies)
Interventional - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
Participants
Cystic Fibrosis - 16 Years and older (Child, Adult, Older Adult)
Interventions
Combination Product: ABCI|Combination Product: Placebo
Outcome measures
Adverse Events (AEs), and Serious Adverse Events (SAEs)|Pharmacokinetics (PK) Profile - SAD Cmax|Pharmacokinetics (PK) Profile - SAD Tmax|Pharmacokinetics (PK) Profile - SAD AUC0-24|Pharmacokinetics (PK) Profile - SAD AUClast|Pharmacokinetics (PK) Profile - SAD AUCinf|Pharmacokinetics (PK) Profile - MAD Cmax|Pharmacokinetics (PK) Profile - MAD Tmax|Pharmacokinetics (PK) Profile - MAD AUC0-24|Pharmacokinetics (PK) Profile - SAD AUCtau|Pharmacokinetics (PK) Profile - MAD Plasma AmB trough assessments|Pharmacokinetics (PK) Profile - MAD AmB concentrations in BAL fluid|Pharmacokinetics (PK) Profile - Subjects with CF Cmax|Pharmacokinetics (PK) Profile - Subjects with CF Tmax|Pharmacokinetics (PK) Profile - Subjects with CF AUC0-24|Pharmacokinetics (PK) Profile - Subjects with CF AUCtau|Pharmacokinetics (PK) Profile - Subjects with CF trough AmB concentrations|Pharmacokinetics (PK) Profile - Subjects with CF Plasma AmB trough assessments|FEV1 - Subjects with CF|Questionnaire - Subjects with CF|FVC - Subjects with CF|Body weight - Subjects with CF